G Y Song1, C S Chung, I H Chaudry, A Ayala. 1. Center for Surgical Research and Department of Surgery, Brown University School of Medicine and Rhode Island Hospital, Providence, 02903, USA.
Abstract
BACKGROUND: Although studies have shown that there is a marked depression in cell-mediated (T(H)(1)) immunity after the onset of sepsis, the mechanism by which this occurs remains unknown. In this regard, the T(H2) cytokine IL-4 is known to regulate T(H1) and T(H2) cell responsiveness primarily through the activation of the signal transducer and activation of transcription factor-6 (Stat6) pathway. METHODS: We hypothesized that IL-4 may contribute to the suppression of cell-mediated immunity and to death seen in sepsis and that IL-4 may be acting through the Stat6 pathway. To determine this, we induced cecal ligation and puncture (CLP) or sham-CLP in male BALB/c mice. Mice received 2 mg of monoclonal antibody against IL-4 or IgG control at 12 hours after CLP (ie, at the onset of immune suppression). Splenic T cells were then isolated 24 hours after CLP and stimulated with monoclonal antibody to CD3. Cytokine release and Stat6 phosphorylation (activation) were determined. In a separate group of animals, survival was assessed over 10 days. RESULTS: The results indicate that after CLP, T cells are suppressed in their ability to release the T(H1) cytokines, IL-2 and IFN-gamma. Alternatively, the release of T(H2) cytokines IL-10 and IL-4 is markedly increased after CLP. This was associated with an increase in phosphorylated Stat6 protein. In vivo treatment of mice with monoclonal antibody to IL-4 at 12 hours after CLP restores T(H1) responsiveness while preventing the increase in T(H2) cytokine release and Stat6 phosphorylation. Furthermore, neutralization of IL-4 markedly increased the survival rates in septic animals. CONCLUSIONS: Taken together, these data indicate that the T(H2) cytokine IL-4 contributes to the suppression of cell-mediated immunity and death associated with polymicrobial sepsis and suggest that IL-4 may be acting through the Stat6 pathway in septic animals.
BACKGROUND: Although studies have shown that there is a marked depression in cell-mediated (T(H)(1)) immunity after the onset of sepsis, the mechanism by which this occurs remains unknown. In this regard, the T(H2) cytokine IL-4 is known to regulate T(H1) and T(H2) cell responsiveness primarily through the activation of the signal transducer and activation of transcription factor-6 (Stat6) pathway. METHODS: We hypothesized that IL-4 may contribute to the suppression of cell-mediated immunity and to death seen in sepsis and that IL-4 may be acting through the Stat6 pathway. To determine this, we induced cecal ligation and puncture (CLP) or sham-CLP in male BALB/c mice. Mice received 2 mg of monoclonal antibody against IL-4 or IgG control at 12 hours after CLP (ie, at the onset of immune suppression). Splenic T cells were then isolated 24 hours after CLP and stimulated with monoclonal antibody to CD3. Cytokine release and Stat6 phosphorylation (activation) were determined. In a separate group of animals, survival was assessed over 10 days. RESULTS: The results indicate that after CLP, T cells are suppressed in their ability to release the T(H1) cytokines, IL-2 and IFN-gamma. Alternatively, the release of T(H2) cytokines IL-10 and IL-4 is markedly increased after CLP. This was associated with an increase in phosphorylated Stat6 protein. In vivo treatment of mice with monoclonal antibody to IL-4 at 12 hours after CLP restores T(H1) responsiveness while preventing the increase in T(H2) cytokine release and Stat6 phosphorylation. Furthermore, neutralization of IL-4 markedly increased the survival rates in septic animals. CONCLUSIONS: Taken together, these data indicate that the T(H2) cytokine IL-4 contributes to the suppression of cell-mediated immunity and death associated with polymicrobial sepsis and suggest that IL-4 may be acting through the Stat6 pathway in septic animals.
Authors: Grace Y Song; Chun-Shiang Chung; Rebecca J Rhee; William G Cioffi; Alfred Ayala Journal: Intensive Care Med Date: 2005-09-20 Impact factor: 17.440
Authors: Alfred Ayala; Yanli Ding; Rebecca J Rhee; Lesley A Doughty; Patrician S Grutkoski; Chun-Shiang Chung Journal: Rec Res Dev Immunol Date: 2003-01-12
Authors: Albert Dahdah; Gregory Gautier; Tarik Attout; Frédéric Fiore; Emeline Lebourdais; Rasha Msallam; Marc Daëron; Renato C Monteiro; Marc Benhamou; Nicolas Charles; Jean Davoust; Ulrich Blank; Bernard Malissen; Pierre Launay Journal: J Clin Invest Date: 2014-09-02 Impact factor: 14.808
Authors: Hina Chaudhry; Juhua Zhou; Yin Zhong; Mir Mustafa Ali; Franklin McGuire; Prakash S Nagarkatti; Mitzi Nagarkatti Journal: In Vivo Date: 2013 Nov-Dec Impact factor: 2.155
Authors: Daniele C Nascimento; Paulo H Melo; Annie R Piñeros; Raphael G Ferreira; David F Colón; Paula B Donate; Fernanda V Castanheira; Aline Gozzi; Paula G Czaikoski; Wanda Niedbala; Marcos C Borges; Dario S Zamboni; Foo Y Liew; Fernando Q Cunha; Jose C Alves-Filho Journal: Nat Commun Date: 2017-04-04 Impact factor: 14.919